PT  - JOURNAL ARTICLE
AU  - D W Rosenberg
TI  - Pharmacokinetics of cobalt chloride and cobalt-protoporphyrin.
DP  - 1993 Sep 01
TA  - Drug Metabolism and Disposition
PG  - 846--849
VI  - 21
IP  - 5
4099  - http://dmd.aspetjournals.org/content/21/5/846.short
4100  - http://dmd.aspetjournals.org/content/21/5/846.full
SO  - Drug Metab Dispos1993 Sep 01; 21
AB  - A comparison of the pharmacokinetics of the trace element cobalt and the protoporphyrin chelate of this metal, cobalt-protoporphyrin, was conducted in male Sprague-Dawley rats. Following subcutaneous treatment (250 mumol/kg body weight), cobalt was found predominantly (> 95%) in plasma, from which it was rapidly eliminated (t1/2 approximately 25 hr). Cobalt-protoporphyrin, also found almost exclusively in plasma (> 95%), exhibited a much slower elimination rate (approximately 3 days) in comparison to the noncomplexed metal. Four weeks after dosing with either inorganic cobalt or cobalt-protoporphyrin, tissue levels of cobalt were measured by graphite furnace atomic absorption spectroscopy. The kidney retained the highest levels of cobalt (1 and 4 micrograms/g dry tissue weight, respectively), although in cobalt-protoporphyrin-treated rats, elevated levels of cobalt (1.5 micrograms/g) were still observed in the spleen, gonads, lung, and thymus up to 4 weeks posttreatment. These differences in pharmacokinetics between inorganic cobalt and cobalt-protoporphyrin are discussed in terms of the differing biological properties exhibited by the metal in its different chemical associations.